Downloads
-
Leveraging Conventional Therapeutics Skills For Cell And Gene Therapy
2/6/2026
Cell and gene therapies share fundamental objectives with conventional biologics. Their common challenges offer a natural starting point to solving downstream bottlenecks.
-
Selecting A Prefillable Syringe System With Confidence
2/5/2026
Discover an advancement in the prefillable syringe market, uniquely integrating the syringe barrel, plunger, and needle shield/tip cap into a fully harmonized, verified system from a single supplier.
-
Smart Scaling For Cell And Gene Therapies
2/5/2026
To meet patient demand, advanced therapy manufacturing processes must be commercial ready. CGT sponsors can mitigate risk and protect viability by partnering with a CDMO that prioritizes scalability.
-
Sterile Filtration Of Cell Debris
2/5/2026
AccuStrain™ 40μm & 150μm Filters are designed and packaged for bioprocessing applications, providing filtration of cell aggregates and extraneous particulate removal in cell separation, media preparation, and final fill workflows.
-
Biologics Discovery Capabilities
2/4/2026
Accelerate your biologics program with an integrated discovery‑to‑development partner built to deliver high‑quality candidates with speed and scientific rigor.
-
Antibody Discovery & Engineering Services
2/4/2026
The Curia Antibody Center offers a comprehensive suite of services for researchers seeking the discovery and engineering of potent and functional antibodies.
-
Bispecific Antibodies Unleashed
2/4/2026
Explore how leveraging expert CDMO partnerships can streamline the development process and enhance the efficacy of your bispecific antibody therapies.
-
The Current And Future Value Of mRNA Vaccines And Therapeutics
2/4/2026
Discover how decades of research have propelled mRNA technology to the forefront of therapeutic development and learn how our expertise is advancing mRNA drug development.
-
The Benefits Of End-To-End Formulation And Fill/Finish Of Biologics
2/4/2026
Proper formulation development has a huge impact on whether a technology transfer to clinical phase fill/finish is successful. Review the challenges of transitioning a promising drug candidate.
-
Leveraging Efficiency From CLD To Clinical Manufacturing Of mAbs
2/4/2026
Discover how our efficient strategies can propel your mAb from discovery to clinical manufacturing in as little as 18 months.